

Prospects & Overviews

Snake venom: From fieldwork to the clinic

Recent insights into snake biology, together with new technology allowing high-throughput screening of venom, bring new hope for drug discovery

Freek J. Vonk^{1)2)*}, Kate Jackson^{3)*}, Robin Doley⁴⁾, Frank Madaras⁵⁾, Peter J. Mirtschin⁵⁾ and Nicolas Vidal⁶⁾

Snake venoms are recognized here as a grossly underexplored resource in pharmacological prospecting. Discoveries in snake systematics demonstrate that former taxonomic bias in research has led to the neglect of thousands of species of potential medical use. Recent discoveries reveal an unexpectedly vast degree of variation in venom composition among snakes, from different species down to litter mates. The molecular mechanisms underlying this diversity are only beginning to be understood. However, the enormous potential that this resource represents for pharmacological prospecting is clear. New high-throughput screening systems offer greatly increased speed and efficiency in identifying and extracting therapeutically useful molecules. At the same time a global biodiversity crisis is threatening the very snake populations on which hopes for new venom-derived medications depend. Biomedical researchers, pharmacologists, clinicians, herpetologists, and conservation biologists must combine their efforts if the full potential of snake venom-derived medications is to be realized.

Keywords:

■ drug; screening; snake; toxin; venom

Introduction

Snakes are represented on earth today by some 3,150 species [1]. Of these the vast majority (ca. 2,700 species, see Fig. 1) represent a single massive diversification event that occurred after the K-T boundary and extinction of the dinosaurs. This large and relatively recent group is known as Caenophidia or “advanced snakes”, and characterized by the possession of a venom-delivery system or components of such a system [2]. Snakes traditionally considered venomous are the 600 or so species with tubular front fangs, muscularized venom glands, and a bite significantly dangerous to humans (Viperidae, Elapidae, and Atractaspidinae) – including well-known examples such as the cobras, sea snakes, vipers, and rattlesnakes. The remaining caenophidians were traditionally classified as “Colubridae”, meaning snakes with a venom gland whose venom poses no danger to humans, and who lack the fangs at the front of the mouth for injecting it. The “Colubridae” has been shown to be paraphyletic, and most of

DOI 10.1002/bies.201000117

¹⁾ Leiden University, Institute of Biology, Sylvius Laboratory, Leiden, The Netherlands

²⁾ Netherlands Centre for Biodiversity Naturalis, Leiden, The Netherlands

³⁾ Department of Biology, Whitman College, Walla Walla, WA, USA

⁴⁾ Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur, India

⁵⁾ Venom Science Pty Ltd., Tanunda, SA, Australia

⁶⁾ Département Systématique et Evolution, UMR 7138, Muséum National d'Histoire Naturelle, Paris, France

*Corresponding authors:

Freek J. Vonk

E-mail: f.j.vonk@biology.leidenuniv.nl

Kate Jackson

E-mail: jacksok@whitman.edu

Abbreviations:

ASSET, accelerated segment switch in exons to alter targeting; **CRISP**, cysteine-rich secretory protein; **CVF**, cobra venom factor; **PLA2**, phospholipase A2; **SVMP**, snake venom metalloproteinase; **3FTX**, three-finger toxin.




Figure 1. Phylogenetic tree showing the distribution of 28 snake venom protein families among advanced snakes, with the number of currently known species of each family and the number of red listed species. Families in gray used to make up the old traditional "Colubridae". Phylogeny based on [1, 103]. Acn, acetylcholinesterase; BNP, B-type natriuretic peptide; C3B, FAMC3B cytokine; CNP-BPP, C-type natriuretic peptide-bradykinin-potentiating peptide; GrTx, glycine-rich toxin; Hya, hyaluronidase; LAO, L-amino acid oxidase; MMP, matrix metalloproteinases; NGF, nerve growth factor; RAP, renin-like aspartic protease; VEGF, vascular endothelial growth factor.

its subfamilies have recently been elevated to a familial rank to reflect their evolutionary distinctiveness (Fig. 1) [1, 3].

"Colubrid" snakes have been largely neglected in venom research, because of the sole fact that bites have not been perceived as of medical importance, except few species such as the African boomslang (*Dispholidus typus*) and twig snakes (*Thelotornis* spp.) and the Asian yamakagashi (*Rhabdophis tigrinus*). However, during the last few years, there has been a trend towards studying the venoms of these harmless venomous snakes to, primarily, increase our understanding of venom evolution. It became evident that these harmless snakes do secrete a strong-acting venom with powerful toxins, although in a significantly lower amount and without an efficient injection mechanism [2, 4]. This influenced the ongoing quest for venom molecules that may be useful in fighting human disease – a snake need not be dangerous to humans for its venom to still have a profound effect upon the human body. This field of biodiscovery is now rapidly emerging, especially due to the development of modern high-throughput screening assays that allow rapid identification of potential therapeutic agents.

Snake venom contains a mixture of powerful proteins and peptides that have evolved to be targeted to receptors, ion channels or enzymes [5], in addition to some carbohydrates, nucleosides, lipids, and metal ions, whose functions are not all known [6, 7]. They interact with a wide variety of mammalian proteins and can disrupt the central and peripheral nervous systems, the blood coagulation cascade, the cardiovascular and neuromuscular systems, and homeostasis in general. These venom proteins act with great precision – different toxins recognize different subtypes of certain receptors with only subtle differences – and are very biologically active. The precision and power with which they work lies right at the center of why they form such a valuable resource to biochemists, biomedical researchers, evolutionary biologists and others.

Several major human drugs or diagnostics have been developed based on snake venom components. In addition, some fundamental biological processes have been revealed using toxins as probes to study cells and their receptors. Here we review the state of this field and emphasize that the emerging field of high-throughput screening assays applied to a wide range of unstudied venoms has the potential to provide a solid basis for the discovery of new lead compounds for new drugs.

Forces driving evolutionary divergence in venom composition: Diet, phylogeny, biogeography, and ontogeny

Only in relatively recent years has the remarkable variability of venom composition at the genus, species, subspecies, population, and even individual levels been fully appreciated, and a start has been made to identify and understand the underlying ecological forces and mechanisms of mutation at the molecular level. Variation in venom composition has far-reaching implications. For the treatment of snakebite, for example, the importance of using pooled venom (mixtures of venom from several individuals of the same species representing different ages and geographical origins) has been emphasized in the production of antivenom to produce – in some cases – a serum that will be maximally effective against a bite from any snake of that species [8]. However, it should be noted that many antivenoms provide excellent – sometimes even better – cross-reactions against antigens not even included in the original mixture, a phenomenon that is not yet well understood.

Since different species of prey differ in their physiological reaction to venom molecules, it follows that venom composition is linked to diet and varies from the species level all the

way to individuals. In saw-scaled vipers (*Echis*), venom from those species that feed on arthropods was highly toxic to scorpions [9]. By contrast, scorpions were unaffected by venom from those species that feed on mammals [9]. Phylogenetic analysis revealed repeated instances of co-evolution of venom composition with prey preference. Other examples of variation in venom composition correlated with diet, at the individual to the species level, have been found in coral snakes (*Micrurus*) [10], rattlesnakes (*Crotalus* and *Sistrurus*) [8, 11–13], Malayan pitvipers (*Calloselasma*) [14], lanceheads (*Bothrops*) [15, 16], puff adders (*Bitis arietans*) [17], and others.

Specificity of venom to prey type has also been found by studies approaching the question by analyzing the composition of the venom. A single species of coral snake (*Micrurus s. surinamensis*), distinctive within its genus in feeding on fish, was found to have venom containing neurotoxins lethal to fish and not known from the venom of other *Micrurus* species [10]. Significant differences in the protein composition were also found in the venoms of three subspecies of the rattlesnake *Sistrurus catenatus*, attributable to dietary differences between the subspecies [18]. Of the 11 protein families represented in the venom of this species, variation between the subspecies was found in all protein families, but variation was greater in some than in others. The metalloproteinases proved to be the most conserved while the phospholipases A2 (PLA2s) were the most divergent. PLA2s are often associated with neurotoxins – i.e. the neurotoxin molecules also have PLA2 activity (e.g. notexin, taipoxin, crotoxin, β -bungarotoxin, etc.), so it could be that the neurotoxins vary more to accommodate the different prey types. Some toxins may assist in prey breakdown (digestion) but others – like neurotoxins causing paralysis or hemotoxins causing rapid low blood pressure or circulation – are perhaps more critical, they may determine whether the snake gets the meal in the first place.

In addition to diet, other variables such as phylogeny, biogeography, and ontogeny may also be forces driving the evolutionary divergence of venom proteins (these factors may well be correlated with diet in many cases) – and perhaps just even separation time between populations due to genetic drift [19]. Although most studies documenting variation attribute it to a single factor, considering these categories in isolation may result in an incomplete understanding of the true scenario. For example, individuals of the common lancehead (*Bothrops asper*) from two different localities and of different ages displayed significant differences in venom proteome [20]. Variation in symptoms of bite victims from individuals of this species varying in age or geographic origin has been observed though never formally documented. Ontogenetic differences in venom compositions are most probably explained by ontogenetic shifts in diet [21]. The venom of neonates was found to differ significantly from that of adults, with a trend toward increasing complexity with age [21]. In the proteomes of neonate and adult individuals of the rattlesnake *Crotalus simus* the venom of adults and neonates had only 50% of their proteome in common, with a trend from neurotoxic to hemorrhagic properties from neonate to adult [22].

While ontogenetic variation certainly, and biogeographical variation in some cases, may well be explained by variation

in prey type, observations of variation in the venom proteome of male versus female neonates from a single litter of the South American viper *Bothrops jararaca* [23] are puzzling and underscore just how much remains to be learned about the evolutionary forces driving variation in venom composition.

For the pharmacological prospector, variation is right at the heart of the potential goldmine of molecules that snake venom represents, since a high degree of variation in venom composition increases the number of potentially useful novel molecules. Recognizing the crucial biomedical significance of variation in venom underscores the importance of efforts by those field biologists working with snakes to understand and conserve biological diversity, from the species down to the individual level. This emphasizes the importance of fieldwork in biodiscovery and the collection of venom samples from a wide range of species and specimens of different geographical localities and ages (Fig. 2).

Sources of toxin diversity: Multiple splicing, exon insertion, exon switching, post-translational modification, and domain switching

Snake toxin genes are the result of gene duplications of normal body proteins that are subsequently selectively expressed in the venom gland [24], often followed by accelerated point mutations in the protein coding regions [5]. Gene duplication creates redundancy and allows the duplicated gene to escape the pressures of negative selection and acquire new functions through accelerated adaptive molecular evolution [5]. Acetylcholinesterase is the only currently known exception, because both the toxin and the normal enzyme are encoded by the same gene but differentially expressed using alternative splicing (see Fig. 3A) [25].

The molecular mechanisms that cause accelerated evolution – a bias towards nucleotide mutations that lead to amino acid changes (nonsynonymous substitutions) compared to those that do not (synonymous substitutions) – are currently not understood. When the first snake genome becomes available, this may shed light upon the molecular mechanisms that operate on the venom genes. Interestingly, nucleotide sequences appear to determine the accelerated rate of point mutations [25]. Specific triplets were found to be more “stable” with regards to mutations than others, and the stable triplets were found to be higher in abundance in venom introns, while the non-stable triplets were found higher in abundance in venom exons. There also appears to be a bias for transversions over transitions in nucleotide substitutions in some toxins [26].

There are several mechanisms by which molecular diversity of venom toxins is generated. First, alternative splicing allows multiple different functional proteins to be created using the same exons (Fig. 3A) [27, 28] as this may cause binding to different receptors [29] or change of target altogether. Second, exons may be inserted into existing genes – as in denmotoxin (Fig. 3B), a three-finger toxin (3FTX) in the venom of the “colubrid” mangrove catsnake (*Boiga dendrophila*) with bird-specific activity [30]. Third, part of the intron



Figure 2. Because of the enormous diversity in venom composition and the accelerated evolution of different isoforms of each of the toxin types in Fig. 1, fieldwork is essential to obtain samples from a wide range of species and specimens of different geographical localities and ages to exploit the full pharmacological potential of venom. **A:** A rare species of “colubrid”, the green tree snake (*Dipsadoboa viridis*), in the Republic of Congo (Africa) (photo by K.J.). **B:** One of the authors (F.J.V.) with a wild King cobra (*Ophiophagus hannah*) – the longest venomous snake in the world – on the island of Java in Indonesia (photo by Smarley). **C:** The same author obtaining a venom sample from an Australian King brown (*Pseudechis rossignoli*) (photo by H-W Herrmann). **D:** One of the authors (K.J.) removing a watersnake (*Grayia ornata*), mimic of the venomous Water cobra (*Naja annulata*) from a net in the Republic of Congo.

may be retained in the mRNA due to error in splicing (Fig. 3C). Also, a recently discovered mechanism termed accelerated segment switch in exons to alter targeting (ASSET) may play an important role in generating the molecular diversity in snake venom molecules [31] (Fig. 3D). During ASSET certain parts of exons are changed through accelerated segment switch and generate a functionally new toxin with a conserved structural fold. Sometimes, synergistic action between two different toxins may enhance their potency [32, 33].

Post-translational modifications such as disulfide bridge formation and proteolysis play important roles in structural modification and acquisition of new functional sites. Both covalent and non-covalent interactions between similar and dissimilar proteins can form complexes that may exhibit a much higher pharmacological activity compared to the individual components. Sometimes formation of hetero/homo dimeric or trimeric complexes may lead to recognition of new targets, as protein-protein interaction in complexes may expose critical amino acid residues that were otherwise buried in monomers [26].

New interaction sites are also formed in certain proteins to exhibit higher pharmacological potencies through domain swapping. In domain swapping, exchange of identical structural elements takes place between two or more molecules to form dimers or oligomers. For example, with the exchange of domains by α and β subunits of IX/X binding protein, isolated from the venom of the Okinawa habu (*Protobothrops flavoviridis*) [34], the hinge region forms a concave structure between the subunits and provides a new functional site in the

heterodimer [26]. Without this swapping the loop would fold back and the ligand binding site would be absent.

Snake venom enzymes and toxins

Of the following enzymes, some have currently been described in all snake venoms, and others from only a limited number of species: PLA2s, metalloproteinases, serine proteases, acetylcholinesterases, L-amino acid oxidases, and hyaluronidases (Fig. 1). Two important and diverse families are the PLA2s and the metalloproteinases. PLA2 enzymes exhibit a wide variety of pharmacological effects in prey/victims and are therefore interesting for the pharmacological prospector [35]. Catalytically inactive Lys49 PLA2 homologs – found in many viperid venoms and being strongly myotoxic – work through a hydrolysis-independent mechanism [36]. Furthermore, although differing in their pharmacological and enzymatic activity, the PLA2-like and PLA2 toxins are highly similar in sequence and structure, and differ only for the substitution of Asp-49 with Lys or Ser [37] – an example of how puzzling the mechanisms of toxicity can be. Some of the neurotoxic PLA2 are either homo/heterodimeric complexes. For example, β -bungarotoxin contains a covalently linked Kunitz-type serine protease inhibitor, which is involved in the blocking activity [38].

Snake venom metalloproteinases (SVMPs) are responsible for major local symptoms in snakebite, causing hemorrhage, edema, hypotension, hypovolemia, inflammation and necrosis.




Figure 3. Some molecular mechanisms by which the diversity of toxin proteins is achieved. **A:** Normal and alternative splicing, as in acetylcholinesterase [25]. **B:** Insertion of exon, as in dendrotoxin [30]. **C:** Intron retention due to error in splicing. **D:** Accelerated segment switch in exons to alter targeting (ASSET) as observed in a 3FTX from the venom of the rattlesnake *Sistrurus catenatus* [31]. Short sequences (segments) in exons are radically changed to unrelated sequences and affect the folding and functional properties. Colored segments (red, purple, pink, yellow) represent exchanges of segments.

They are divided into three groups (P-I to P-III) based on the presence of other domains in the mature protein [39]. P-I SVMs have a prodomain and a single metalloproteinase domain that overall causes less hemorrhagic action than the other types, but still displays a variety of biological activities. The P-II SVMs are composed of a metalloproteinase and disintegrin domain, along with a prodomain.

Non-enzymatic venom proteins include 3FTXs, Kunitz-type serine protease inhibitors, sarafotoxins, cysteine-rich secretory protein (CRISP), disintegrins, C-type lectins, waprins, veficolins, and vespryns. 3FTXs have three beta-stranded loops resembling three-fingers and are mainly found in the venoms of elapids, some “colubrids” [30, 40] and, in low quantity, some viperids [41, 42]. The structure is stabilized by four conserved disulfide bridges [43, 44]. However, these structurally related molecules differ greatly in their biological functions [45, 46]. Functional characterization of this family of proteins has contributed significantly to our understanding of the mechanisms of venom toxicity and of normal physiological processes [46]. For example, characterization of α -bungarotoxin, a three-finger neurotoxin found in the venom of the banded krait (*Bungarus multicinctus*), enabled the isolation of the human nicotinic acetylcholine receptor (nAChR) [47] and contributed to our understanding of myasthenia gravis [48]. Significant contributions have been made in determining the distribution of specific receptors or ion channels in particular tissues or cells, identification of subtypes of receptors, imaging receptor trafficking [49–51] as well as in the development

of therapeutic agents for treatment of adrenomyeloneuropathy and multiple sclerosis [52].

Snake venom Kunitz-type serine protease inhibitors like dendrotoxin, calcicludine and the B chain of β -bungarotoxin, act as Ca^{2+} and K^{+} channel blockers, respectively [53–55]. Textilinin, a Kunitz-type serine protease inhibitor from the venom of the highly dangerous Australian brown snake (*Pseudonaja textilis*) is a reversible plasmin inhibitor and has promising potential for development of anti-bleeding agent [56].

Waprins have only recently been identified in snake venom and show homology to whey acidic proteins [57]. So far their functions are not really understood except for omwaprins, isolated from the Inland taipan (*Oxyuranus microlepidotus*), which possesses selective antimicrobial activities [58], useful for developing potential antibiotics.

CRISP toxins have molecular mass of 20–30 kDa and 16 conserved cysteine residues. Functional characterization of some CRISP has revealed that they are involved in blocking cyclic nucleotide-gated ion channels and block potassium-stimulated smooth muscle contraction [59]. Therefore, in addition to their involvement in disrupting the normal physiological functions of victims, they can be used for studying ion channel chemistry. A CRISP toxin from the venom of the “colubrid” snake the Patagonia green racer (*Philodryas patagoniensis*) was recently shown to cause damage to the murine gastrocnemius muscle, an action never before shown for any CRISP toxin [60] – showing the potential for finding new toxins in “colubrid” venoms.

Snake venom C-type lectins (Snaclecs) comprise two subclasses of protein, C-type lectins (CTLs) and C-type lectin-related proteins (CLRPs), found in venoms of most families of advanced snakes. Snake venom CTLs are involved in hemagglutinating and platelet aggregation activities during envenomation [61–64]. The CLRPs are involved in anticoagulant, procoagulant and agonist/antagonist of platelet activation [65, 66]. Pharmacological characterization reveals that they either enhance or inhibit the function of coagulation factors, which underscores their potential in drug discovery for blood-related diseases. Their immaculate specificity also helps in understanding platelet physiology.

Disintegrins are a class of non-enzymatic venom proteins that bind to integrins $\alpha\text{IIb}\beta_3$, $\alpha_5\beta_1$, and $\alpha_3\beta_3$ expressed on platelets and other vascular endothelial cells as well as some tumor cells [67] – they are an important class of cell surface receptors that are critically involved in cell-cell and cell-matrix interactions and are therefore good candidates in helping to understand the interaction between extracellular matrix and cells [68]. In addition to their role in antiplatelet activity, these molecules are used in the diagnosis of cardiovascular diseases and serve as prototypes for therapeutic molecules in treatment of cancer.

Medicinal use of snake venom

A large number of venom proteins affect the hemostatic system [69] and can have procoagulant, anticoagulant, fibrinolytic, or platelet active activities. Ancrod (Arvin) from the venom of the Malayan pitviper (*Calloselasma rhodostoma*), batroxobin (Reptilase) from the common lancehead (*Bothrops atrox*), and crotalase from the Eastern diamondback rattlesnake (*Crotalus adamanteus*) have all been used as defibrinogenating agents for several clinical conditions including deep vein thrombosis, myocardial infarction, pulmonary embolus, and many others [70]. Venoms with anticoagulant properties are extensively studied for possible medical applications. The drug Aggrastat (tirofiban) was developed from a compound in the venom of the saw-scaled viper (*Echis carinatus*), and is used as an antiplatelet drug (glycoprotein IIb/IIIa inhibitors) [71] and given to those with unstable angina (Fig. 4). Many

venoms with procoagulant properties find application in the diagnosis of clotting abnormalities, and most of the clotting pathways can be assayed by some venom component, e.g. “reptilase time” (*B. atrox*) assays for thrombin inhibitors [72], “Ecarin” (*E. carinatus*) and “taipan time” (*Oxyuranus scutellatus*) assays for prothrombin, and Russell’s viper (*Daboia russelii*) venom assays for factor X and for monitoring anticoagulant therapy [73].

A number of snake venoms create a transient condition of depressed blood pressure in envenomed patients. Angiotensin-converting enzyme (ACE) inhibitors were developed from a bradykinin-potentiating enzyme isolated from the venom of the Brazilian pitviper (*Bothrops jararaca*) and approved in 1979 by the FDA [74] to treat high-blood pressure and heart disease (Fig. 5). They work by blocking the switch between angiotensin-I and angiotensin-II, the latter being a vasoconstrictor. These inhibitors are now prescribed worldwide and have saved the lives of millions.

Many venoms have analgesic properties. Hannalgesin, derived from the venom of the King cobra (*Ophiophagus hannah*, see Fig. 2B) is already in clinical trials [75]. Promising toxins have been isolated from the tropical rattlesnake (*Crotalus durissus terrificus*) and some other related species. Compounds derived from the Asiatic cobra (*Naja kaouthia*) are already in use in alternative medicine. Being more powerful than morphine, cobra venom was used in the 1930s for treating intractable pain in cancer sufferers.

There is great deal of research currently being done into the anticancer properties of venoms. For example, malignant brain and spinal-cord tumors (gliomas) are not curable by surgery because they invade the surrounding brain tissue without clear boundaries, making removal impossible. Disintegrins, like contortrostatin from American copperhead (*Agkistrodon contortrix*) venom, prevent cells from sticking together, and inhibit their interaction with surrounding tissue, resulting in a blockage of cell motility and invasiveness [76]. It has been demonstrated that fibrin(ogen) plays separate and distinctive roles at different stages of tumor growth and dissemination. At the primary site, fibrin deposition around the tumor could form a protective barrier, but also limit tumor progression. On the other hand, fibrin deposits formed by metastatic tumor cells may help disseminating these tumor




Figure 4. Mechanisms of action of the anticoagulant Aggrastat developed from a compound in the venom of the Indian saw-scaled viper (*Echis carinatus*). **A:** Aggregated platelets by formation of fibrinogen bridges between the glycoprotein IIb/IIIa receptors. **B:** Glycoprotein IIb/IIIa receptor antagonists like Aggrastat prevent platelet aggregation, and are mainly used in patients with acute coronary syndromes.




Figure 5. Mechanism of action of ACE inhibitors developed from a bradykinin-potentiating enzyme isolated from the venom of the Brazilian pitviper (*Bothrops jararaca*) and approved in 1979 by the FDA [74] to treat high blood pressure and heart disease. Angiotensin-I causes vasoconstriction which raises the blood pressure.

cells [77]. Anticoagulants and the removal of fibrin could be an effective therapy. One of the earliest reports on the successful use of a venom defibrinogenating enzyme was that of Wood and Hilgard [78].

Many cobra venoms contain cobra venom factor (CVF), which activates and depletes the mammalian immune-complement system [79]. They are structural and functional analogues of the mammalian serum complement factor C3 [80]. CVF is used as a tool to study various aspects of the complement system, and in this respect CVF is a uniquely useful venom component that has also been found useful as an immunosuppressant agent in tissue transplantation and in cancer therapy [81].

Many venoms have antibacterial properties. For example, Stiles et al. [82] found two antibacterial bioactive L-amino acid oxidase components in King brown (*Pseudechis australis*) venom that were 70 and 17.5 times more effective in vitro than tetracycline, a drug of choice for *Aeromonas* infections. Antibacterial and antiparasitic effects of the venom of the Marajó lancehead (*Bothrops marajoensis*) were shown to be caused by PLA2 and L-amino acid oxidase toxins [83].

Antiviral activity has been demonstrated in several venoms, although no commercialization of any of these compounds has yet taken place. The venom of the tropical rattlesnake (*Crotalus durissus terrificus*) from Brazil has been shown to be active against the measles virus [84]. The purified PLA2 venom neurotoxin “taipoxin” from the coastal taipan (*O. scutellatus*), Nigexine from the African black necked cobra (*Naja nigricolis*) and a basic PLA2 from the Mozambique spitting cobra (*Naja mossambica*) have been shown to have potent antiviral activities against HIV-1 virus [85].

Myasthenia gravis, a chronic autoimmune disorder affecting 2 out of every 100,000 people, results in progressive skeletal muscle weakness with rapid fatigue and loss of strength. It primarily affects mastication, facial and swallowing muscles and in advanced cases, respiratory muscles. Autoimmune antibodies destroy acetylcholine receptor sites at the neuromuscular junctions, preventing nerve impulses from reaching the muscles. A rapid, quantitative and sensitive

radioimmunoassay using human acetylcholine receptor, affinity labeled with purified neurotoxin (α -bungarotoxin, from the venom of the Taiwan krait *Bungarus multicinctus*) is used to diagnose the condition [48, 86]. Most venoms possessing α -neurotoxins are potential candidates for this purpose.

High-throughput screening to identify potential new medicines in venoms

A major obstacle in exploring snake venom for new leads into drug discovery is the low amount of venom usually obtained during the process of milking (extracting venom from the venom glands of a live snake, see Fig. 2C). In addition, it is difficult to extract venom from many of the “colubrid” snakes. Because of this, venom research has focused mainly on those snakes that are dangerous to humans, but this does not necessarily reflect the potential of their venom for drug discovery. Some of the harmless “colubrid” venom toxins have been shown to be as potent as those of some deadly elapids, only produced in small amounts [4, 87]. For example, the venoms of the Patagonia green racer (*Philodryas patagoniensis*) and Lichtenstein’s green racer (*P. olfersii*) have been shown to possess high proteolytic activity, degrading fibrinogen and the vascular wall [88], and strong edematogenic and myotoxic activity [89], respectively. In addition, a completely new family of toxins has recently been found in the venom of the Asian dog-faced water snake (*Cerberus rynchops*). These toxins, called veficolins, may induce platelet aggregation and/or initiate complement activation [90]. Hence, the bias towards deadly snakes in exploring venoms for drug discovery is completely unwarranted.

Alternatively, with the use of molecular tools, the venom gland transcriptome can be explored. Using this approach not only can the expression profile and the evolution of the venom proteins be determined [91], but also the lowly expressed proteins can be revealed, which will expand our resource for pharmaceutically active molecules.

Many of the medically significant venomous snakes produce ~100–200 mg dry venom in a single milking [92]. Large

species of elapids and viperids may produce from several hundred milligrams up to more than a gram of venom in a single milking [92]. The recently described giant spitting cobra (*Naja ashei*) has been shown to produce the immense amount of 3 g of weight of dry venom [93], the largest amount ever collected during a single milking. The amount of venom that a snake produces during milking is determined by the species, its geographic origin, its body size and relative head size, and by the time of the year that it is milked, as well as by interactions among these factors, body size being the primary factor [94].

When biomedical researchers are looking for lead therapeutic agents against diseases, they can first look at those venoms of which the snakebite symptoms involve the same pathways as the disease, for example, using venom that causes vasodilatation to look for potential blood pressure regulators. However, snake venom is very complex and contains many different isoforms, some of which may only be present in very low quantities in the venom. Nerve growth factor is only present in a concentration of about 0.1–0.5% [95]. A fraction that stimulates neurite outgrowth was first identified in tumor cell extracts, but venom from cottonmouth vipers (*Agkistrodon piscivorus*) was then found to be up to 6,000 times more potent [96] – a discovery that allowed the authors to study the mechanisms regulating cell and organ growth, for which they were awarded the Nobel prize in 1986. The problem is that venom compounds that are present only in low concentrations do not necessarily contribute to the bite symptomology and may thus be easily overlooked, although they can be of high potential biomedical interest. To exploit the full potential of snake venoms, a wide variety of them need to be fractionated and all fractions tested separately in a high-throughput screen of interest. Mice have typically been used as model organisms, e.g. in identifying genes involved in pain and anxiety, and in screening for analgesic peptides [97]. However, using mice is ethically controversial and low-throughput screens also require relatively large amounts of the precious venoms. Zebrafish (*Danio rerio*) are being increasingly used as model organisms to screen for new drugs, and this provides a significant window of opportunity for screening snake venom (or venom from other venomous animals). Zebrafish are cheaper to maintain than rodents, their eggs and embryos are transparent so that phenotypic changes can be visualized, and they can be easily scaled up into high-throughput assays [98] that require minimal amounts of venom; automated imaging and analysis systems are also available [99, 100]. Morpholino knockdowns can be performed by injecting the yolk sac of embryos, allowing live imaging studies, and many disease-related genes identified in humans have orthologs in zebrafish [98]. Although zebrafish will never replace mammalian models completely in the drug development pipeline, they do form a cost-effective bridge between cell-based models on the one hand and rodent whole-organism models on the other [98].

Conservation of snakes

A recent report by conservation biologists [101] documented a disturbing trend – a global decline in non-related snake species occurring over the world during the same time.

Although they only looked at a small number of snakes (17 populations of eight species), we need to keep in mind that any species of snake that goes extinct may have held a new drug in its venom. Species having small home ranges, sedentary habits and ambush feeding strategies are likely to be the most vulnerable since they rely on sites with specific types of ground cover that are disrupted by anthropogenic activities, and since ambush foraging is associated with a suite of life-history traits that involve low rates of feeding, growth and reproduction [102].

Current research on snake venoms is phylogenetically biased. Of the 1,622 snake venom toxin sequences available on Universal Protein Resource database, only 49 are sequenced from snakes that do not possess any danger to humans. However, with the high-throughput systems currently being developed this may hopefully soon change.

Very few data actually exist on the true conservation status of snakes worldwide. Out of 2,711 extant caenophidian species, 26 are CITES listed, i.e. less than 1%, while 967 are listed on the IUCN Red List of Threatened Species, i.e. 36%. The main grounds identified for their threatened status are caused by humans: annual and perennial non-timber crops (272 species), logging and wood harvesting (179 species), housing and urban areas (143 species), livestock farming and ranching (98 species), hunting and trapping (64 species) and natural system modifications (57 species). Although the majority of the species listed have been categorized as Least Concern (60%), this does not necessarily reflect their true status [101], and for another 22% of the species the data are insufficient to categorize them accordingly. In addition, 87% of the species (837) have been added to the Red List since 2007, highlighting the lack of proper attention in the years before.

If biogeography is considered, relatively well protected regions are North America (123 red listed species), Central America (325 species), the Philippines (84 species) and Europe (29 species). On the other hand, several biodiversity hotspots such as South America (113 species), Sub-Saharan Africa (82 species), and the Caribbean Islands (16 species), among others are neglected, although these areas may represent the locations with the highest potential for discovering snake species new to science, each representing new potential for advancing the frontiers of clinical medicine.

Conclusions and future perspectives

While the use of snake venom for medicinal purposes dates back to ancient times, the past few decades have seen several new drugs derived from components of snake venom becoming available to patients worldwide. Here, we have reviewed recent advances in areas ranging from evolutionary to molecular biology that, taken altogether, indicate new possibilities for contributions to clinical medicine and medical research from snake venom. First, advances in snake systematics demonstrate a high degree of phylogenetic bias in previous molecular prospecting in snake venom, increasing the number of species from which medically useful molecules may be obtained. Secondly, discoveries in snake venom composition have revealed an unexpectedly high degree of variation of snake venoms of the same species linked to variables

such as diet, geographical distribution, and ontogeny. These two factors increase the potential pool that snake venom represents for pharmacological prospecting. In addition, new and innovative techniques in high-throughput systems offer increased speed and efficiency in identifying and extracting desirable molecules from snake venom. In conclusion, we emphasize the challenges faced in the conservation of snake biodiversity, since it is ultimately on this that hopes for the development of new therapeutic agents from snake venom depends.

Acknowledgments

We are grateful to M. K. Richardson, R. M. Kini and M. Goyffon for help in critically reading and commenting on the manuscript. This work was supported by a TopTalent grant from the Netherlands Organization for Scientific Research (NWO; F.J.V.), the Leiden University Fund (F.J.V.) and two grants from the The Herpetofauna Foundation (F.J.V.).

References

- Vidal N, Delmas AS, David P, Cruaud C, et al. 2007. The phylogeny and classification of caenophidian snakes inferred from seven nuclear protein-coding genes. *C R Biol* **330**: 182–7.
- Vonk FJ, Admiraal JF, Jackson K, Reshef R, et al. 2008. Evolutionary origin and development of snake fangs. *Nature* **454**: 630–3.
- Lawson R, Slowinski JB, Crother BI, Burbrink FT. 2005. Phylogeny of the Colubroidea (Serpentes): new evidence from mitochondrial and nuclear genes. *Mol Phylogenet Evol* **37**: 581–601.
- Fry BG, Lumsden NG, Wuster W, Wickramaratna JC, et al. 2003. Isolation of a neurotoxin (alpha-colubritoxin) from a nonvenomous colubrid: evidence for early origin of venom in snakes. *J Mol Evol* **57**: 446–52.
- Calvete JJ. 2009. Venomics: digging into the evolution of venomous systems and learning to twist nature to fight pathology. *J Proteomics* **72**: 121–6.
- Fox JW, Serrano SM. 2008. Exploring snake venom proteomes: multifaceted analyses for complex toxin mixtures. *Proteomics* **8**: 909–20.
- Georgieva D, Arni RK, Betzel C. 2008. Proteome analysis of snake venom toxins: pharmacological insights. *Expert Rev Proteomics* **5**: 787–97.
- Gibbs HL, Sanz L, Calvete JJ. 2009. Snake population venomics: proteomics-based analyses of individual variation reveals significant gene regulation effects on venom protein expression in *Sistrurus* rattlesnakes. *J Mol Evol* **68**: 113–25.
- Barlow A, Pook CE, Harrison RA, Wuster W. 2009. Coevolution of diet and prey-specific venom activity supports the role of selection in snake venom evolution. *Proc Biol Sci* **276**: 2443–9.
- Olamendi-Portugal T, Batista CV, Restano-Cassulini R, Pando V, et al. 2008. Proteomic analysis of the venom from the fish eating coral snake *Micrurus surinamensis*: novel toxins, their function and phylogeny. *Proteomics* **8**: 1919–32.
- Oguiura N, Collares MA, Furtado MF, Ferrarezzi H, et al. 2009. Intraspecific variation of the crotoamine and crotoasin genes in *Crotalus durissus* rattlesnakes. *Gene* **446**: 35–40.
- Gibbs HL, Mackessy SP. 2009. Functional basis of a molecular adaptation: prey-specific toxic effects of venom from *Sistrurus* rattlesnakes. *Toxicon* **53**: 672–9.
- Salazar AM, Guerrero B, Cantu B, Cantu E, et al. 2009. Venom variation in hemostasis of the southern Pacific rattlesnake (*Crotalus oreganus helleri*): isolation of hellerase. *Comp Biochem Physiol C Toxicol Pharmacol* **149**: 307–16.
- Daltry JC, Wuster W, Thorpe RS. 1996. Diet and snake venom evolution. *Nature* **379**: 537–40.
- Gutierrez JM, Sanz L, Flores-Diaz M, Figueroa L, et al. 2010. Impact of regional variation in *Bothrops asper* snake venom on the design of antivenoms: integrating antivenomics and neutralization approaches. *J Proteome Res* **9**: 564–77.
- Salazar AM, Rodriguez-Acosta A, Giron ME, Aguilar I, et al. 2007. A comparative analysis of the clotting and fibrinolytic activities of the snake venom (*Bothrops atrox*) from different geographical areas in Venezuela. *Thromb Res* **120**: 95–104.
- Currier RB, Harrison RA, Rowley PD, Laing GD, et al. 2010. Intra-specific variation in venom of the African Puff Adder (*Bitis arietans*): differential expression and activity of snake venom metalloproteinases (SVMPs). *Toxicon* **55**: 864–73.
- Sanz L, Gibbs HL, Mackessy SP, Calvete JJ. 2006. Venom proteomes of closely related *Sistrurus* rattlesnakes with divergent diets. *J Proteome Res* **5**: 2098–112.
- Williams V, White J, Schwaner TD, Sparrow A. 1988. Variation in venom proteins from isolated populations of tiger snakes (*Notechis ater niger*, *N. scutatus*) in South Australia. *Toxicon* **26**: 1067–75.
- Alape-Giron A, Flores-Diaz M, Sanz L, Madrigal M, et al. 2009. Studies on the venom proteome of *Bothrops asper*: perspectives and applications. *Toxicon* **54**: 938–48.
- Antunes TC, Yamashita KM, Barbaro KC, Saiki M, et al. 2010. Comparative analysis of newborn and adult *Bothrops jararaca* snake venoms. *Toxicon* **56**: 1443–58.
- Calvete JJ, Sanz L, Cid P, de la Torre P, et al. 2010. Snake venomics of the Central American rattlesnake *Crotalus simus* and the South American *Crotalus durissus* complex points to neurotoxicity as an adaptive pae-domorphic trend along *Crotalus* dispersal in South America. *J Proteome Res* **9**: 528–44.
- Menezes MC, Furtado MF, Travaglia-Cardoso SR, Camargo AC, et al. 2006. Sex-based individual variation of snake venom proteome among eighteen *Bothrops jararaca* siblings. *Toxicon* **47**: 304–12.
- Kini RM, Chan YM. 1999. Accelerated evolution and molecular surface of venom phospholipase A2 enzymes. *J Mol Evol* **48**: 125–32.
- Kini RM, Chinnasamy A. 2010. Nucleotide sequence determines the accelerated rate of point mutations. *Toxicon* **56**: 295–304.
- Doley R, Kini RM. 2009. Protein complexes in snake venom. *Cell Mol Life Sci* **66**: 2851–71.
- Fujimi TJ, Nakajyo T, Nishimura E, Ogura E, et al. 2003. Molecular evolution and diversification of snake toxin genes, revealed by analysis of intron sequences. *Gene* **313**: 111–8.
- Tamiya T, Ohno S, Nishimura E, Fujimi TJ, et al. 1999. Complete nucleotide sequences of cDNAs encoding long chain alpha-neurotoxins from sea krait, *Laticauda semifasciata*. *Toxicon* **37**: 181–5.
- Servent D, Winckler-Dietrich V, Hu HY, Kessler P, et al. 1997. Only snake curaremimetic toxins with a fifth disulfide bond have high affinity for the neuronal alpha7 nicotinic receptor. *J Biol Chem* **272**: 24279–86.
- Pawlak J, Mackessy SP, Fry BG, Bhatia M, et al. 2006. Denmotoxin, a three-finger toxin from the colubrid snake *Boiga dendrophila* (Mangrove Catsnake) with bird-specific activity. *J Biol Chem* **281**: 29030–41.
- Doley R, Mackessy SP, Kini RM. 2009. Role of accelerated segment switch in exons to alter targeting (ASSET) in the molecular evolution of snake venom proteins. *BMC Evol Biol* **9**: 146.
- Chang CC, Chen TF, Lee CY. 1973. Studies of the presynaptic effect of -bungarotoxin on neuromuscular transmission. *J Pharmacol Exp Ther* **184**: 339–45.
- Habermann E, Breithaupt H. 1978. Mini-review. The crotoxin complex – an example of biochemical and pharmacological protein complementation. *Toxicon* **16**: 19–30.
- Atoda H, Morita T. 1989. A novel blood coagulation factor IX/factor X-binding protein with anticoagulant activity from the venom of *Trimeresurus flavoviridis* (Habu snake): isolation and characterization. *J Biochem (Tokyo)* **106**: 808–13.
- Kini RM. 1997. *Phospholipase A2 A Complex Multifunctional Protein Puzzle*. Chichester: John Wiley & Sons.
- Bonfim VL, de Carvalho DD, Ponce-Soto LA, Kassab BH, et al. 2009. Toxicity of phospholipases A2 D49 (6-1 and 6-2) and K49 (Bj-VII) from *Bothrops jararacussu* venom. *Cell Biol Toxicol* **25**: 523–32.
- de Paula RC, Castro HC, Rodrigues CR, Melo PA, et al. 2009. Structural and pharmacological features of phospholipases A2 from snake venoms. *Protein Pept Lett* **16**: 899–907.
- Benishin CG. 1990. Potassium channel blockade by the B subunit of beta-bungarotoxin. *Mol Pharmacol* **38**: 164–9.
- Hite LA, Jia LG, Bjarnason JB, Fox JW. 1994. cDNA sequences for four snake venom metalloproteinases: structure, classification, and their relationship to mammalian reproductive proteins. *Arch Biochem Biophys* **308**: 182–91.
- Pawlak J, Mackessy SP, Sixberry NM, Stura EA, et al. 2009. Irditoxin, a novel covalently linked heterodimeric three-finger toxin with high taxon-specific neurotoxicity. *FASEB J* **23**: 534–45.

41. Jiang M, Haggblad J, Heilbronn E. 1987. Isolation and pharmacological characterization of a new alpha-neurotoxin (alpha-AgTx) from venom of the viper *Agkistrodon halys* (Pallas). *Toxicon* **25**: 1019–22.
42. Pahari S, Mackessy SP, Kini MR. 2007. The venom gland transcriptome of the Desert Massasauga Rattlesnake (*Sistrurus catenatus edwardsii*): towards an understanding of venom composition among advanced snakes (Superfamily Colubroidea). *BMC Mol Biol* **8**: 115.
43. Menez A. 1998. Functional architectures of animal toxins: a clue to drug design? *Toxicon* **36**: 1557–72.
44. Tsetlin V. 1999. Snake venom alpha-neurotoxins and other 'three-finger' proteins. *Eur J Biochem* **264**: 281–6.
45. Kini RM. 2002. Molecular moulds with multiple missions: functional sites in three-finger toxins. *Clin Exp Pharmacol Physiol* **29**: 815–22.
46. Kini RM, Doley R. 2010. Structure, function and evolution of three-finger toxins – mini proteins with multiple targets. *Toxicon* **56**: 855–67.
47. Nirthanan S, Gwee MC. 2004. Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on. *J Pharmacol Sci* **94**: 1–17.
48. Chu NS. 2005. Contribution of a snake venom toxin to myasthenia gravis: the discovery of alpha-bungarotoxin in Taiwan. *J Hist Neurosci* **14**: 138–48.
49. Mulugeta E, Karlsson E, Islam A, Kalaria R, et al. 2003. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. *Brain Res* **960**: 259–62.
50. Sekine-Aizawa Y, Haganir RL. 2004. Imaging of receptor trafficking by using alpha-bungarotoxin-binding-site-tagged receptors. *Proc Natl Acad Sci USA* **101**: 17114–9.
51. Tsetlin V, Shelukhina I, Kryukova E, Burbaeva G, et al. 2007. Detection of alpha7 nicotinic acetylcholine receptors with the aid of antibodies and toxins. *Life Sci* **80**: 2202–5.
52. Reid PF. 2007. Alpha-cobratoxin as a possible therapy for multiple sclerosis: a review of the literature leading to its development for this application. *Crit Rev Immunol* **27**: 291–302.
53. Gilquin B, Lecoq A, Desne F, Guenneugues M, et al. 1999. Conformational and functional variability supported by the BPTI fold: solution structure of the Ca²⁺ channel blocker calcicludine. *Proteins* **34**: 520–32.
54. Harvey AL, Karlsson E. 1980. Dendrotoxin from the venom of the green mamba, *Dendroaspis angusticeps*. A neurotoxin that enhances acetylcholine release at neuromuscular junction. *Naunyn Schmiedeberg's Arch Pharmacol* **312**: 1–6.
55. Joubert FJ, Taljaard N. 1979. Snake venoms. The amino-acid sequence of protein S2C4 from *Dendroaspis jamesoni kaimosae* (Jameson's mamba) venom. *Hoppe Seyler's Z Physiol Chem* **360**: 571–80.
56. Millers EK, Trabi M, Masci PP, Lavin MF, et al. 2009. Crystal structure of textilin-1, a Kunitz-type serine protease inhibitor from the venom of the Australian common brown snake (*Pseudonaja textilis*). *FEBS J* **276**: 3163–75.
57. Torres AM, Wong HY, Desai M, Mochhala S, et al. 2003. Identification of a novel family of proteins in snake venoms. Purification and structural characterization of nawaprin from *Naja nigricollis* snake venom. *J Biol Chem* **278**: 40097–104.
58. Nair DG, Fry BG, Alewood P, Kumar PP, et al. 2007. Antimicrobial activity of omwaprin, a new member of the waprins family of snake venom proteins. *Biochem J* **402**: 93–104.
59. Shikamoto Y, Suto K, Yamazaki Y, Morita T, et al. 2005. Crystal structure of a CRISP family Ca²⁺-channel blocker derived from snake venom. *J Mol Biol* **350**: 735–43.
60. Peichoto ME, Mackessy SP, Teibler P, Tavares FL, et al. 2009. Purification and characterization of a cysteine-rich secretory protein from *Philodryas patagoniensis* snake venom. *Comp Biochem Physiol C Toxicol Pharmacol* **150**: 79–84.
61. Clemetson KJ, Polgar J, Clemetson JM. 1998. Snake venom C-type lectins as tools in platelet research. *Platelets* **9**: 165–9.
62. Clemetson KJ, Navdaev A, Dormann D, Du XY, et al. 2001. Multifunctional snake C-type lectins affecting platelets. *Haemostasis* **31**: 148–54.
63. Hirabayashi J, Kusunoki T, Kasai K. 1991. Complete primary structure of a galactose-specific lectin from the venom of the rattlesnake *Crotalus atrox*. Homologies with Ca²⁺-dependent-type lectins. *J Biol Chem* **266**: 2320–6.
64. Lin LP, Lin Q, Wang YQ. 2007. Cloning, expression and characterization of two C-type lectins from the venom gland of *Bungarus multicinctus*. *Toxicon* **50**: 411–9.
65. Drickamer K. 1993. Recognition of complex carbohydrates by Ca²⁺-dependent animal lectins. *Biochem Soc Trans* **21**: 456–9.
66. Morita T. 2004. C-type lectin-related proteins from snake venoms. *Curr Drug Targets Cardiovasc Haematol Disord* **4**: 357–73.
67. Gould RJ, Polokoff MA, Friedman PA, Huang TF, et al. 1990. Disintegrins: a family of integrin inhibitory proteins from viper venoms. *Proc Soc Exp Biol Med* **195**: 168–71.
68. Lin E, Wang Q, Swenson S, Jadvar H, et al. 2010. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. *Prostate* **70**: 1359–70.
69. Markland FS, Jr. 1998. Snake venom fibrinolytic and fibrinolytic enzymes: an updated inventory. Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost* **79**: 668–74.
70. Markland FS. 1998. Snake venoms and the hemostatic system. *Toxicon* **36**: 1749–800.
71. Hartman GD, Egbertson MS, Halczenko W, Laswell WL, et al. 1992. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. *J Med Chem* **35**: 4640–2.
72. Funk C, Gmur J, Herold R, Straub PW. 1971. Reptilase-R – a new reagent in blood coagulation. *Br J Haematol* **21**: 43–52.
73. Madaras F, Chew MY, Parkin JD. 1981. Automated estimation of factor Xa using the chromogenic substrate S-2222. *Haemostasis* **10**: 271–5.
74. Cushman DW, Cheung HS, Sabo EF, Rubin B, et al. 1979. Development of specific inhibitors of angiotensin I converting enzyme (kininase II). *Fed Proc* **38**: 2778–82.
75. Pu XC, Wong PT, Gopalakrishnakone P. 1995. A novel analgesic toxin (hannalgesin) from the venom of king cobra (*Ophiophagus hannah*). *Toxicon* **33**: 1425–31.
76. Trikha M, De Clerck YA, Markland FS. 1994. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. *Cancer Res* **54**: 4993–8.
77. DeWys WD, Kwaan HC, Bathina S. 1976. Effect of defibrination on tumor growth and response to chemotherapy. *Cancer Res* **36**: 3584–7.
78. Wood S, Jr. Hilgard PH. 1973. Arvin-induced hypofibrinogenemia and metastasis formation from blood-borne cancer cells. *Johns Hopkins Med J* **133**: 207–13.
79. Eggertsen G, Lind P, Sjoquist J. 1981. Molecular characterization of the complement activating protein in the venom of the Indian cobra (*Naja n. siamensis*). *Mol Immunol* **18**: 125–33.
80. Vogt W. 1990. *Snake Venom Constituents Affecting the Complement System*. Boca Raton: CRC Press.
81. Vogel C-W. 1987. *Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer*. New York: Oxford University Press.
82. Stiles BG, Sexton FW, Weinstein SA. 1991. Antibacterial effects of different snake venoms: purification and characterization of antibacterial proteins from *Pseudechis australis* (Australian king brown or mulga snake) venom. *Toxicon* **29**: 1129–41.
83. Costa Torres AF, Dantas RT, Toyama MH, Diz FE, et al. 2010. Antibacterial and antiparasitic effects of *Bothrops marajoensis* venom and its fractions: phospholipase A2 and L-amino acid oxidase. *Toxicon* **55**: 795–804.
84. Petricevich VL, Mendonca RZ. 2003. Inhibitory potential of *Crotalus durissus terrificus* venom on measles virus growth. *Toxicon* **42**: 143–53.
85. Fenard D, Lambeau G, Valentin E, Lefebvre JC, et al. 1999. Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. *J Clin Invest* **104**: 611–8.
86. Vincent A. 2002. Unravelling the pathogenesis of myasthenia gravis. *Nat Rev Immunol* **2**: 797–804.
87. Zelanis A, da Teixeira R, de Fatima MM, Domingues FM. 2010. Preliminary biochemical characterization of the venoms of five Colubridae species from Brazil. *Toxicon* **55**: 666–9.
88. Acosta O, Leiva LC, Peichoto ME, Marunak S, et al. 2003. Hemorrhagic activity of the Duvernoy's gland secretion of the xenodontine colubrid *Philodryas patagoniensis* from the north-east region of Argentina. *Toxicon* **41**: 1007–12.
89. Acosta de Pérez O, Leiva de Vila L, Peichoto ME, Marunak S, et al. 2003. Edematogenic and myotoxic activities of the Duvernoy's gland secretion of *Philodryas olfersii* from the north-east region of Argentina. *Biocell* **27**: 363–70.
90. Ompraba G, Chapeaurouge A, Doley R, Devi KR, et al. 2010. Identification of a novel family of snake venom proteins veficolins from *Cerberus rynchops* using a venom gland transcriptomics and proteomics approach. *J Proteome Res* **9**: 1882–93.

91. **Junqueira-de-Azevedo IL, Ching AT, Carvalho E, Faria F, et al.** 2006. *Lachesis muta* (Viperidae) cDNAs reveal diverging pit viper molecules and scaffolds typical of cobra (Elapidae) venoms: implications for snake toxin repertoire evolution. *Genetics* **173**: 877–89.
92. **Mirtschin PJ, Dunstan N, Hough B, Hamilton E, et al.** 2006. Venom yields from Australian and some other species of snakes. *Ecotoxicology* **15**: 531–8.
93. **Wuster W, Broadley DG.** 2007. Get an eyeful of this: a new species of giant spitting cobra from eastern and north-eastern Africa (Squamata: Serpentes: Elapidae: Naja). *Zootaxa* **1532**: 51–68.
94. **Mirtschin PJ, Shine R, Nias TJ, Dunstan NL, et al.** 2002. Influences on venom yield in Australian tigersnakes (*Notechis scutatus*) and brown-snakes (*Pseudonaja textilis*: Elapidae, Serpentes). *Toxicon* **40**: 1581–92.
95. **Kostiza T, Meier J.** 1996. Nerve growth factors from snake venoms: chemical properties, mode of action and biological significance. *Toxicon* **34**: 787–806.
96. **Cohen S, Levi-Montalcini R.** 1956. A nerve growth-stimulating factor isolated from snake venom. *Proc Natl Acad Sci USA* **42**: 571–4.
97. **Callahan BL, Gil AS, Levesque A, Mogil JS.** 2008. Modulation of mechanical and thermal nociceptive sensitivity in the laboratory mouse by behavioral state. *J Pain* **9**: 174–84.
98. **Brittijn SA, Duivesteijn SJ, Belmamoune M, Bertens LF, et al.** 2009. Zebrafish development and regeneration: new tools for biomedical research. *Int J Dev Biol* **53**: 835–50.
99. **Vogt A, Codore H, Day BW, Hukriede NA, et al.** 2010. Development of automated imaging and analysis for zebrafish chemical screens. *J Vis Exp* **40**. DOI: 10.3791/1900.
100. **Vogt A, Cholewinski A, Shen X, Nelson SG, et al.** 2009. Automated image-based phenotypic analysis in zebrafish embryos. *Dev Dyn* **238**: 656–63.
101. **Reading CJ, Luiselli LM, Akani GC, Bonnet X, et al.** 2010. Are snake populations in widespread decline? *Biol Lett* **6**: 777–80.
102. **Shine R, Reed RN, Shetty S, Lemaster M, et al.** 2002. Reproductive isolating mechanisms between two sympatric sibling species of sea snakes. *Evolution* **56**: 1655–62.
103. **Fry BG, Scheib H, van der Weerd L, Young B, et al.** 2008. Evolution of an arsenal: structural and functional diversification of the venom system in the advanced snakes (Caenophidia). *Mol Cell Proteomics* **7**: 215–46.